Skip to main content
NCBI home page
Atencion Primaria logoLink to Atencion Primaria
. 2013 Apr 5;25(7):512–517. [Article in Spanish] doi: 10.1016/S0212-6567(00)78557-X

Papel de las nuevas fluoroquinolonas en las infecciones respiratorias en atención primaria

C Llor Vilà 1, MA Mayer Pujadas 1, JM Cots Yago 1
PMCID: PMC7679621  PMID: 10917693

The content is available as a PDF (89.5 KB).

Bibliografía

  • 1.Mandell G.L., Petri W.A. Antimicrobial agents: sulfonamides, trimethroprim-sulfamethoxazole, quinolones, and agents for urinarytract infections. In: Hardman J.G., Limbird L.E., editors. Goodman and Gilman's basis of therapeutics. 9.a. McGraw-Hill; Nueva York:: 1996. pp. 1057–1072. [Google Scholar]
  • 2.Borcherding S.M., Stevens R., Nicholas R.A., Corley C.R., Self T. Quinolones: a practical review of clinical uses, dosing considerations, and drug interactions. J Fam Pract. 1996;42:69–78. [PubMed] [Google Scholar]
  • 3.National Committee for Clinical Laboratory Standards Performance standards for antimicrobial susceptibility testing. Sixth International Supplement. NCCLS Document. 1995;15(n.° 14) M100-S6 Villanova, PA. [Google Scholar]
  • 4.Pallarés R., Linares J., Vadillo M., Cabellos C., Manresa F., Viladrich P.F. Resistance to penicillin and cephalosporins and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N Engl J Med. 1995;333:474–480. doi: 10.1056/NEJM199508243330802. [DOI] [PubMed] [Google Scholar]
  • 5.Gaztelorrutia L., Zalacaín R., Rubio G., Hernández J.L., Urra E., Hernández M. Actualidad de la penicilina en las neumonías neumocócicas extrahospitalarias. Enferm Infecc Microbiol Clin. 1994;12:17–20. [PubMed] [Google Scholar]
  • 6.García J. Situación epidemiológica actual y resistencia de los patógenos respiratorios en España. Med Clin (Barc) 1998;110(Supl 1):44–51. [PubMed] [Google Scholar]
  • 7.Sánchez F., Narváez A., Iglesias R., García-Oñive E., Iñíguez R., Sánchez J.F. Resistencias a penicilina y eritromicina en neumonías neumocócicas extrahospitalarias. Enferm Infecc Microbiol Clin. 1994;12:475. [PubMed] [Google Scholar]
  • 8.Musher D.M. Pneumococcal outbreaks in nursing homes. N Engl J Med. 1998;338:1915–1916. doi: 10.1056/NEJM199806253382610. [DOI] [PubMed] [Google Scholar]
  • 9.Pankuch G.A., Visalli M.A., Jacobs M.R., Appelbaum P.C. Activities of oral and parenteral agents against penicillinsusceptible and resistant pneumococci. Antimicrob Agents Chemother. 1995;39:1499–1504. doi: 10.1128/aac.39.7.1499. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Aguilar R., Rosendo J., Balcabao I.P., Martín M., Giménez M.J., Frías J. Pharmacodinamic effects of amoxycillin versus cefotaxime against penicillin-susceptible and penicillin-resistant pneumoccocal strains: a phase I study. Antimicrob Agents Chemother. 1997;41:1389–1391. doi: 10.1128/aac.41.6.1389. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Schwarzmann S.W. Novel cost-effective approaches to the treatment of community-acquired infections. Ann Pharmacother. 1998;32:S27–S30. doi: 10.1177/106002809803200107. [DOI] [PubMed] [Google Scholar]
  • 12.Verhaegen J., Verbist L. In-vitro activity of 21 beta-lactam antibiotics against penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae. J Antimicrob Chemother. 1998;41:381–385. doi: 10.1093/jac/41.3.381. [DOI] [PubMed] [Google Scholar]
  • 13.Spencer J., González L., Miler R.P., Myers M.L. Treatment of penicillin-resistant pneumococcus with penicillin: a case report. J Fam Pract. 1997;44:499–503. [PubMed] [Google Scholar]
  • 14.Liñares J., Tubau F. Resistencia a cefalosporinas en infecciones por Streptococcus pneumoniae. Med Clin (Barc) 1998;110(Supl 1):21–24. [PubMed] [Google Scholar]
  • 15.Alonso M.A., Gutiérrez M.N., Muñoz J.L., García J.A. Resistencia a macrólidos, lincosamidas y estreptograminas en infecciones por Streptococcus pneumoniae. Med Clin (Barc) 1998;110(Supl 1):25–30. [PubMed] [Google Scholar]
  • 16.Baquero F. Trends in antibiotic resistance of respiratory pathogens: an analysis and commentary on a collaborative surveillance study. J Antimicrob Chemother. 1997;38(Supl A):117–132. doi: 10.1093/jac/38.suppl_a.117. [DOI] [PubMed] [Google Scholar]
  • 17.García J y Grupo Español para Vigilancia de Patógenos Respiratorios Situación epidemiológica actual y resistencia de los patógenos respiratorios en España. Med Clin (Barc) 1998;110(Supl 1):44–51. [PubMed] [Google Scholar]
  • 18.Rodríguez C., Yáñez R., Rodríguez I., Picazo J.J. Resistencia intrínseca de Haemophilus influenzae a los betalactámicos. Med Clin (Barc) 1998;110(Supl 1):52–59. [PubMed] [Google Scholar]
  • 19.Perea E.J. Actividad de los macrólidos sobre Haemophilus influenzae: una revisión clínica. Med Clin (Barc) 1998;110(Supl 1):60–64. [PubMed] [Google Scholar]
  • 20.Hooper D.C. Expanding uses of fluoroquinolones: opportunities and challenges. Ann Intern Med. 1998;129:908–910. doi: 10.7326/0003-4819-129-11_part_1-199812010-00015. [DOI] [PubMed] [Google Scholar]
  • 21.Alarcón T., López-Brea M. Mecanismo de acción y resistencias a fluoroquinolonas. Enferm Infecc Microbiol Clin. 1996;107:472–476. [PubMed] [Google Scholar]
  • 22.Baquero F., Negri M.C., Morosini M.I., Blázquez J. Antibiotic-selective environments. Clin Infect Dis. 1998;27(Supl 1):5–11. doi: 10.1086/514916. [DOI] [PubMed] [Google Scholar]
  • 23.Aguilar J.M., Chacón J., Cantón R., Baquero F. The emergence of highly fluoroquinolone-resistant Escherichia coli in community-acquired urinary tract infections. J Antimicrob Chemother. 1991;29:349–350. doi: 10.1093/jac/29.3.349. [DOI] [PubMed] [Google Scholar]
  • 24.Acar J.F., Goldstein F.W. Trends in bacterial resistance to fluoroquinolones. Clin Infect Dis. 1997;24(Supl 1):67–73. doi: 10.1093/clinids/24.supplement_1.s67. [DOI] [PubMed] [Google Scholar]
  • 25.Cooper B., Lawlor M. Pneumococcal bacteremia during ciprofloxacin therapy with ciprofloxacin. Am J Med. 1989;89:383–384. doi: 10.1016/s0002-9343(89)80838-1. [DOI] [PubMed] [Google Scholar]
  • 26.Garau J. Papel de las quinolonas en el tratamiento de la neumonía adquirida en la comunidad. Med Clin (Barc) 1998;110(Supl 1):31–35. [PubMed] [Google Scholar]
  • 27.Martin S.J., Meyer J.M., Chuck S.K., Jung R., Messick C.R., Pendland S.L. Levofloxacin and sparfloxacin: new quinolone antibiotics. Ann Pharmacother. 1998;32:320–326. doi: 10.1345/aph.17178. [DOI] [PubMed] [Google Scholar]
  • 28.Cohen M.A., Huband M.D., Gage J.W., Yoder S.L., Roland G.E., Gracheck S.J. In-vitro activity of clinofloxacin, trovafloxacin, and ciprofloxacin. J Antimicrob Chemother. 1997;40:205–211. doi: 10.1093/jac/40.2.205. [DOI] [PubMed] [Google Scholar]
  • 29.Thornsberry C., Oglivie P., Kahn J., Mauriz Y. Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States in 1996-1997 respiratory season. The Laboratory Investigator Group. Diagn Microbiol Infect Dis. 1997;29:249–257. doi: 10.1016/s0732-8893(97)00195-8. [DOI] [PubMed] [Google Scholar]
  • 30.Wise R., Adams J.M. A comparison of the activity of ciprofloxacin and levofloxacin with other agents against respiratory tract pathogens. J Chemother. 1998;10:276–279. doi: 10.1179/joc.1998.10.4.276. [DOI] [PubMed] [Google Scholar]
  • 31.Edlund C., Sjoestedt S., Nord C.E. Comparative effects of levofloxacin and ofloxacin on the normal oral and intestinal microflora. Scan J Infect Dis. 1997;29:383–386. doi: 10.3109/00365549709011835. [DOI] [PubMed] [Google Scholar]
  • 32.George J., Morrissey I. The bactericidal activity of levoflocain compared with ofloxacin, D-ofloxacin, ciprofloxacin, sparfloxacin and cefotaxime against Streptococcus pneumoniae. J Antimicrob Chemother. 1997;39:719–723. doi: 10.1093/jac/39.6.719. [DOI] [PubMed] [Google Scholar]
  • 33.Gehanno P., Berche P. and the Sinusitis Study Group. Sparfloxacin versus cefuroxime axetil in the treatment of acute purulent sinusitis. J Antimicrob Chemother. 1996;37(Supl A):105–114. doi: 10.1093/jac/37.suppl_a.105. [DOI] [PubMed] [Google Scholar]
  • 34.Chien S.C., Wong F.A., Fowler C.L., Callery-D'Amico S.V., Williams R.R., Nayak R. Double-blind evaluation of the safety and pharmacokinetics multiple oral once-daily 750-milligram and 1-gram doses of levofloxacin in healthy volunteers. Antimic Agents Chemother. 1998;42:885–888. doi: 10.1128/aac.42.4.885. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Pontani D., Washton H., Bouchillon S., Johnson J. Susceptibility of European respiratory tract isolates to trovafloxacin, ciprofloxacin, clarithromycin, azithromycin and ampicillin. Eur J Clin Microbiol Infect Dis. 1998;17:413–419. doi: 10.1007/BF01691574. [DOI] [PubMed] [Google Scholar]
  • 36.Jones R.N., Pfaller M.A., Doern G.V. Comparative antimicrobial activity of trovafloxacin tested against 3049 Streptococcus pneumoniae isolates from the 1997-1998 respiratory infection season. Diagn Microbiol Infect Dis. 1998;32:119–126. doi: 10.1016/s0732-8893(98)00072-8. [DOI] [PubMed] [Google Scholar]
  • 37.Waites K., Brookings E., Nix S., Robinson A., Gray B. Swiatlo. Comparative in vitro activities of four new fluoroquinolones against Streptococcus pneumoniae determined by E-test. Intern J Antimicrob Agents. 1998;9:215–218. doi: 10.1016/s0924-8579(97)00053-8. [DOI] [PubMed] [Google Scholar]
  • 38.Visalli M.A., Bajaksouzians L., Jacobs M.R., Appelbaum P.C. Comparative activity of trovafloxacin, alone and in combination with other agents, against Gram-negative nonfermentative rods. Antimicrob Agents Chemother. 1997;41:1475–1481. doi: 10.1128/aac.41.7.1475. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Pechere J.C., Gootz T.D. Bacteriological activity of trovafloxacin, a new quinolone, against respiratory tract pathogens. Eur J Clin Microbiol Infect Dis. 1998;17:405–412. doi: 10.1007/BF01691573. [DOI] [PubMed] [Google Scholar]
  • 40.Piddock L.J.V., Johnson M., Ricci V., Hill S.L. Activities of new fluoroquinolones against fluoroquinolone-resistant pathogens of the lower respiratory tract. Antimicrob Agents Chemother. 1998;42:2956–2960. doi: 10.1128/aac.42.11.2956. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Alarcón T., Domingo D., Prieto N., Sánchez S., López-Brea M. Actividad in vitro de la trovafloxacina en 238 patógenos respiratorios. Rev Esp Quimioter. 1998;11:47–51. [PubMed] [Google Scholar]
  • 42.Hoogkamp-Korstanje J.A. In-vitro activities of ciprofloxacin, levofloxacin, lomefloxacin, ofloxacin, pefloxacin, sparfloxacin and trovafloxacin against Gram-positive and Gram-negative pathogens from respiratory tract infections. J Antimicrob Chemother. 1997;40:427–431. doi: 10.1093/jac/40.3.427. [DOI] [PubMed] [Google Scholar]
  • 43.Roblin P.M., Kutlin A., Hammerschlag M.R. In vitro activitiy of trovafloxacin against Chlamydia pneumoniae. Antimicrob Agents Chemother. 1997;41:2033–2034. doi: 10.1128/aac.41.9.2033. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Woodhad M. Pneumonia in the elderly. J Antimicrob Chemother. 1994;34(Supl A):85–92. doi: 10.1093/jac/34.suppl_a.85. [DOI] [PubMed] [Google Scholar]
  • 45.Felmingham D., Robbins M.J., Tesfaslasie Y., Harding I., Shrimpton S., Gruneberg R.N. Antimicrobial susceptibility of community-acquired lower respiratory tract bacterial pathogens isolated during the 1995-1996 cold season. J Antimicrob Chemother. 1998;41:411–415. doi: 10.1093/jac/41.3.411. [DOI] [PubMed] [Google Scholar]
  • 46.Schrock J., Hackman B.A., Plouffe J.F. Susceptibility of ninety-eight clinical isolates of Legionella to macrolides and quinolones using the E-test. Diagn Microbiol Infect Dis. 1997;28:221–223. doi: 10.1016/s0732-8893(97)00043-6. [DOI] [PubMed] [Google Scholar]
  • 47.Stahlmann R., Schwabe R. Safety profile of grepafloxacin compared with other fluoroquinolones. J Antimicrob Chemother. 1997;40(Supl A):83–92. doi: 10.1093/jac/40.suppl_1.83. [DOI] [PubMed] [Google Scholar]
  • 48.Williams D., Hopkins S. Safety of trovafloxacin in treatment of lower respiratory tract infections. Eur J Clin Microbiol Infect Dis. 1998;17:454–458. doi: 10.1007/BF01691582. [DOI] [PubMed] [Google Scholar]
  • 49.Anónimo Trovafloxacin. The Medical Letter on Drugs and Therapeutics. 1998;40:30–31. [PubMed] [Google Scholar]
  • 50.Ball P., Mandell L., Niki Y., Tillotson G. Comparative tolerability of the newer fluoroquinolone antibacterials. Drug Safety. 1999;21:407–421. doi: 10.2165/00002018-199921050-00005. [DOI] [PubMed] [Google Scholar]
  • 51.Anónimo Grepafloxacin: a new fluoroquinolone. The Medical Letter on Drugs and Therapeutics. 1998;40:17–18. [PubMed] [Google Scholar]
  • 52.O'Doherty B., Dutchman D.A., Pettit R., Maroli A. Randomized, double-blind, comparative study of grepafloxacin and amoxycillin in the treatment of patients with community-acquired pneumonia. J Antimicrob Chemother. 1997;40(Supl A):73–81. doi: 10.1093/jac/40.suppl_1.73. [DOI] [PubMed] [Google Scholar]
  • 53.Langan C.E., Cranfield R., Breisch S., Pettit R. Randomized, double-blind study of grepafloxacin versus amoxycillin in patients with acute excacerbations of chronic bronchitis. J Antimicrob Chemother. 1997;40(Supl A):63–72. doi: 10.1093/jac/40.suppl_1.63. [DOI] [PubMed] [Google Scholar]
  • 54.O'Doherty B., Daniel R. Treatment of acute exacerbations of chronic bronchitis: comparison of trovafloxacin and amoxicillin in a multicentre, doubleblind, double-dummy study. Trovafloxacin Bronchitis Study Group. Eur J Clin Microbiol Infect Dis. 1998;17:441–446. doi: 10.1007/BF01691580. [DOI] [PubMed] [Google Scholar]
  • 55.Leophonte P., Baldwin R.J., Pluck N. Trovafloxacin versus amoxicillin/clavulanic acid in the treatment of acute exacerbations of chronic obstructive bronchitis. Eur J Clin Microbiol Infect Dis. 1998;17:434–440. doi: 10.1007/BF01691579. [DOI] [PubMed] [Google Scholar]
  • 56.Balfour J.B., Wiseman L.R. Moxifloxacin. Drugs. 1999;57:363–373. doi: 10.2165/00003495-199957030-00007. [DOI] [PubMed] [Google Scholar]
  • 57.Chodosh S., DeAbate C.A., Haverstock D., Aneiro L. Church D and the Bronchitis Study Group. Short-course moxifloxacin therapy for treatment of acute bacterial exacerbations of chronic bronchitis, Respir Med. 2000;94:18–27. doi: 10.1053/rmed.1999.0708. [DOI] [PubMed] [Google Scholar]
  • 58.Marchant C.D., Carlin S.A., Johnson C.E., Shurin P.A. Measuring the comparative efficacy of antibacterial agents for acute otitis media: the «Pollyana» phenomenon. J Pediatr. 1992;120:72–77. doi: 10.1016/s0022-3476(05)80601-8. [DOI] [PubMed] [Google Scholar]
  • 59.Spencer J., González L., Miler R.P., Myers M.L. Treatment of penicillin-resistant Pneumococcus with penicillin: a case report. J Fam Pract. 1997;44:499–503. [PubMed] [Google Scholar]
  • 60.Seppala H., Klaukka T., Vuopio-Varkila J., Muotiala A., Helenius H. Lager K and the Finnish Study Group for Antimicrobial Resistance. The effect of changes in the consumption of macrolide antibiotics on erythromyicin resistance in group A streptococci in Finland. Finnish Study group for Antimicrobial Resistance. N Engl J Med. 1997;14:441–446. doi: 10.1056/NEJM199708143370701. [DOI] [PubMed] [Google Scholar]
  • 61.Liñares J., De la Campa A.G., Pallarés R. Fluoroquinolone resistamce in Streptococcus pneumoniae. N Engl J Med. 1999;341:1546–1548. doi: 10.1056/nejm199911113412013. [DOI] [PubMed] [Google Scholar]
  • 62.Norrby S.R. New fluoroquinolones: towards expanded indications? Current Opinion Infect Dis. 1997;10:440–443. [Google Scholar]

Articles from Atencion Primaria are provided here courtesy of Elsevier

RESOURCES